New therapeutic target to treat inflammation

Scientists from Queen Mary, University of London have identified tiny organelles called primary cilia as a target for anti-inflammation therapy. “Although primary cilia were discovered more than a century ago, we’re only beginning to realize the importance they play in different diseases and conditions, and the potential therapeutic benefits that could be developed from manipulating cilia structure and function,” Martin Knight, who led the research, said. To investigate the role of primary cilia in inflammation, the team of scientists exposed cartilage cells to an inflammatory protein called interleukin-1 (IL-1). What they found was that after just three hours of exposure to IL-1, the primary cilia increase in length by 50 percent. When this elongation of the cilium was treated, the inflammation of the cartilage cells was reduced, suggesting the potential for a new therapeutic target. 

Companies
1
Patents
1
0 Comments
Related Articles
Leyla Raiani
Apr 12, 2012
Boston University researchers identify key regulator of inflammatory response
Researchers at Boston University School of Medicine have identified a gene that plays a key role in regulating inflammatory response... Read More
Elisabeth Manville
Apr 18, 2012
Potential treatment for inflammatory back pain falls short in study
According to the results of a new study led by Johns Hopkins, a new type of injectable, anti-inflammatory pain medicine... Read More
Scientists identify cells that could help unlock the key to treatment-resistant asthma
A research team from the University of Michigan Health system has demonstrated the role of a newly-discovered type of cell... Read More